Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.49 |
| ▸ | KIF11 | P52732 | 5/20 | 0.48 |
| ▸ | MAPKAPK2 | P49137 | 3/20 | 0.47 |
| ▸ | HTR2A | P28223 | 5/20 | 0.45 |
| ▸ | HTR2C | P28335 | 4/20 | 0.45 |
| ▸ | TP53 | P04637 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL949021 | 0.89 | KIF11 (0.47) | KIF11MAPKAPK2TP53MAPTSIRT1 | |
| SCHEMBL944763 | 0.87 | TRPV1 (0.50) | TRPV1KIF11MAPKAPK2HTR2AHTR2C | |
| SCHEMBL945721 | 0.85 | MAPKAPK2 (0.56) | MAPKAPK2TP53MAPT | |
| SCHEMBL946526 | 0.84 | MAPKAPK2 (0.42) | KIF11MAPKAPK2TP53MAPTSIRT1 | |
| SCHEMBL946523 | 0.84 | MAPKAPK2 (0.42) | KIF11MAPKAPK2TP53MAPTSIRT1 | |
| SCHEMBL951334 | 0.81 | S1PR1 (0.60) | MAPKAPK2 | |
| SCHEMBL32666143 | 0.78 | S1PR1 (0.56) | MAPKAPK2HTR2AHTR2CSIRT1 | |
| SCHEMBL944770 | 0.77 | HTR2A (0.68) | MAPKAPK2HTR2AHTR2C | |
| SCHEMBL945075 | 0.77 | S1PR1 (0.53) | — | |
| SCHEMBL946705 | 0.75 | S1PR1 (0.68) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011005295-A1 | MODULATORS OF THE SPHINGOSINE-1-PHOSPHATE (S1P) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2011-01-13 | — | — | WO | disclosed |